Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria

Kasturi L Puranam1, Guanghong Wu, Warren J Strittmatter

  • 1Deane Laboratory, Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA.

Insights

Pathologic-length polyglutamine (PolyQ) protein in Huntington's disease directly impairs mitochondrial respiration and increases oxidative stress. Antioxidants can reverse this mitochondrial dysfunction, suggesting a key role for oxidative damage.

Area of Science:

  • Neuroscience
  • Mitochondrial Biology
  • Genetics

Background:

  • Huntington's disease is a neurodegenerative disorder caused by expanded polyglutamine (PolyQ) tracts in the huntingtin protein.
  • The precise cellular mechanisms driving neurodegeneration in Huntington's disease remain elusive, but mitochondria are implicated.

Purpose of the Study:

  • To investigate the direct impact of pathologic-length PolyQ protein on mitochondrial function.
  • To elucidate the role of mitochondria in the pathogenesis of Huntington's disease.

Main Methods:

  • Isolated mitochondria were used to assess ADP-dependent (state 3) respiration.
  • Activities of electron transport chain complexes, ATP synthase, and adenine nucleotide translocase were measured.
  • Reactive oxygen species (ROS) production was quantified.
  • The effects of antioxidants N-acetyl-L-cysteine and cytochrome c were evaluated.

Main Results:

  • Pathologic-length PolyQ protein directly inhibited state 3 mitochondrial respiration.
  • This inhibition was not caused by reduced activity of key mitochondrial components.
  • PolyQ protein significantly increased ROS production in isolated mitochondria.
  • Antioxidant treatment reversed the impairment of state 3 respiration.

Conclusions:

  • Pathologic-length PolyQ protein directly impairs mitochondrial respiration.
  • Oxidative stress induced by PolyQ protein is a key mechanism in mitochondrial dysfunction in Huntington's disease.
  • Targeting oxidative stress may offer therapeutic potential for Huntington's disease.